Kommentar

• Literatur

• 1 Karpova D, Bräuninger S, Wiercinska E. et al. Mobilization of hematopoietic stem cells with the novel CXCR4 antagonist POL6326 (balixafortide) in healthy volunteers – results of a dose escalation trial. J Transl Med 2017; 15: 2
• 2 Devine SM, Vij R, Rettig M. et al. Rapid mobilization of functional donor hematopoietic cells without G-CSF using AMD3100, an antagonist of the CXCR4/SDF-1 interaction. Blood 2008; 112: 990-998
• 3 Blom B, Ho S, Antonenko S, Liu YJ. Generation of interferon alpha-producing predendritic cell (Pre-DC)2 from human CD34(+) hematopoietic stem cells. J Exp Med 2000; 192: 1785-1796
• 4 Karpova D, Dauber K, Spohn G. et al. The novel CXCR4 antagonist POL5551 mobilizes hematopoietic stem and progenitor cells with greater efficiency than plerixafor. Leukemia 2013; 27: 2322-2331
• 5 Lundqvist A, Smith AL, Takahashi Y. et al. Differences in the phenotype, cytokine gene expression profiles, and in vivo alloreactivity of T cells mobilized with plerixafor compared with G-CSF. J Immunol 2013; 191: 6241-6249